Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial

C Koh, L Canini, H Dahari, X Zhao… - The Lancet Infectious …, 2015 - thelancet.com
Background Therapies for chronic hepatitis delta virus (HDV) infection are unsatisfactory.
Prenylation is essential for HDV and inhibition abrogates HDV production in experimental …
被引用次数：300 相关文章
[HTML] nih.gov

[HTML][HTML] Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial

C Koh, L Canini, H Dahari, X Zhao… - The Lancet. Infectious …, 2015 - ncbi.nlm.nih.gov
Background Therapies for chronic hepatitis delta virus (HDV) infection are unsatisfactory.
Prenylation is essential for HDV and inhibition abrogates HDV production in experimental …

Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial

C Koh, L Canini, H Dahari, X Zhao… - The Lancet Infectious …, 2015 - thelancet.com
Background Therapies for chronic hepatitis delta virus (HDV) infection are unsatisfactory.
Prenylation is essential for HDV and inhibition abrogates HDV production in experimental …
[PDF] eigerbio.com

[PDF][PDF] Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial

C Koh, L Canini, H Dahari, X Zhao, SL Uprichard… - 2015 - eigerbio.com
Background Therapies for chronic hepatitis delta virus (HDV) infection are unsatisfactory.
Prenylation is essential for HDV and inhibition abrogates HDV production in experimental …

Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial

C Koh, L Canini, H Dahari, X Zhao, SL Uprichard… - 2015 - pubmed.ncbi.nlm.nih.gov
Background Therapies for chronic hepatitis delta virus (HDV) infection are unsatisfactory.
Prenylation is essential for HDV and inhibition abrogates HDV production in experimental …
[PDF] ankara.edu.tr

[PDF][PDF] Oral Prenylation Inhibition with Lonafarnib in Chronic Hepatitis D Infection: a randomized, double-blinded, placebo controlled phase 2a trial.

MD Christopher Koh, GS MS, SLC MS, PP MD, EW MD… - 2015 - avesis.ankara.edu.tr
Background: Therapies for chronic delta hepatitis (HDV) infection are unsatisfactory.
Prenylation is essential for HDV and inhibition abrogates HDV production in experimental …

Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial

C Koh, L Canini, H Dahari, X Zhao… - The Lancet Infectious …, 2015 - infona.pl
Therapies for chronic hepatitis delta virus (HDV) infection are unsatisfactory. Prenylation is
essential for HDV and inhibition abrogates HDV production in experimental models. In a …

Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial

C Koh, L Canini, H Dahari, X Zhao, SL Uprichard… - The Lancet Infectious …, 2015 - Elsevier
Background Therapies for chronic hepatitis delta virus (HDV) infection are unsatisfactory.
Prenylation is essential for HDV and inhibition abrogates HDV production in experimental …
[PDF] researchgate.net

[PDF][PDF] Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial

C Koh, L Canini, H Dahari, X Zhao, SL Uprichard… - 2015 - researchgate.net
Background Therapies for chronic hepatitis delta virus (HDV) infection are unsatisfactory.
Prenylation is essential for HDV and inhibition abrogates HDV production in experimental …

Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial

C Koh, L Canini, H Dahari, X Zhao, SL Uprichard… - The Lancet Infectious …, 2015 - osti.gov
Background: Therapies for chronic hepatitis delta virus (HDV) infection are unsatisfactory.
Prenylation is essential for HDV and inhibition abrogates HDV production in experimental …